Recent Study: Netherlands Pharmaceuticals & Healthcare Report Q1 2016

Boston, MA -- (SBWire) -- 11/27/2015 --The Netherlands has a well-developed healthcare system due to generous public expenditure over the years. Despite newly introduced cost - cutting measure s , government spending on healthcare will continue to increase in local currency terms, especially as the wider eurozone recovers. However, the country ' s aging population will put pressure on government finances over the longer-term, inevitably leading to further price caps on medicines.

Headline Expenditure Projections

Pharmaceuticals: EUR5.92bn (USD7.93bn) in 2014 to EUR5.80bn (USD6.38bn) in 2015; -2.0% in local currency terms and -19.6% in US dollar terms. Forecast in line with last quarter.
Healthcare: EUR73.28bn (USD98.19bn) in 2014 to EUR74.29bn (USD81.72bn) in 2015; +1.4% in local currency terms and -16.8% in US dollar terms. Forecast in line with last quarter.

Risk/Reward Index

The Netherlands continues to rank in the lower half of BMI's Risk/Reward Index (RRI) for the 15 key Western European markets, ranking 11th in our index for Q116. At 64.7, its overall RRI score remains unchanged from last quarter and is still slightly below the regional average of 66.8. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.

Get More Details on this Report and a Full Table of Contents at Netherlands Pharmaceuticals & Healthcare Report Q1 2016

The Netherlands Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Netherlands pharmaceutical and healthcare industry.

Key Benefits

-Benchmark BMI's pharmaceutical and healthcare market forecasts for Netherlands, to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
-Target business opportunities and risks in the Dutch pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Netherlands.
-Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI?s forecast analysis, and taken together with BMI?s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

-Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ?000 population).
-Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
-Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
-Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
-OTC Drug Market: OTC sales (USDbn & % of total sales).
-Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI?s Pharmaceuticals and Healthcare Risk Reward Index

BMI?s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market?s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

-Kenya Pharmaceuticals & Healthcare Report Q1 2016
-Thailand Pharmaceuticals & Healthcare Report Q1 2016
-Pakistan Pharmaceuticals & Healthcare Report Q1 2016
-Argentina Pharmaceuticals & Healthcare Report Q1 2016
-Croatia Pharmaceuticals & Healthcare Report Q1 2016